

Holly M Nguyen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10443824/publications.pdf>

Version: 2024-02-01

30
papers

2,674
citations

430874

18
h-index

454955

30
g-index

33
all docs

33
docs citations

33
times ranked

3907
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome. JCI Insight, 2022, 7, .	5.0	9
2	Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer. Cancer Research, 2021, 81, 1583-1594.	0.9	140
3	Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature. PLoS ONE, 2021, 16, e0245602.	2.5	5
4	A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture. Scientific Reports, 2021, 11, 4609.	3.3	14
5	Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nature Communications, 2021, 12, 1979.	12.8	70
6	MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer. Scientific Reports, 2021, 11, 13305.	3.3	20
7	RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. Cancer Research, 2021, 81, 4736-4750.	0.9	18
8	Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nature Communications, 2021, 12, 5775.	12.8	59
9	Caring for the Animal Caregiver – Occupational Health, Human-Animal Bond and Compassion Fatigue. Frontiers in Veterinary Science, 2021, 8, 731003.	2.2	1
10	Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. European Urology, 2020, 77, 144-155.	1.9	46
11	Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer. Clinical Cancer Research, 2020, 26, 1667-1677.	7.0	30
12	Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nature Genetics, 2020, 52, 790-799.	21.4	174
13	Antitumor Activity of the IGF-1/IGF-2 Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models. Molecular Cancer Therapeutics, 2020, 19, 1059-1069.	4.1	12
14	Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer. Oncogene, 2019, 38, 7060-7072.	5.9	31
15	Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma. Journal of Oncology, 2019, 2019, 1-7.	1.3	8
16	Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. Journal of Clinical Investigation, 2019, 129, 4492-4505.	8.2	250
17	High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer. Scientific Reports, 2018, 8, 17239.	3.3	29
18	Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance. Methods in Molecular Biology, 2018, 1786, 1-27.	0.9	7

#	ARTICLE	IF	CITATIONS
19	A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. <i>Clinical Cancer Research</i> , 2018, 24, 4332-4345.	7.0	154
20	Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. <i>Prostate</i> , 2018, 78, 1262-1282.	2.3	76
21	LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics. <i>Prostate</i> , 2017, 77, 654-671.	2.3	219
22	Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts. <i>Clinical Cancer Research</i> , 2017, 23, 2301-2312.	7.0	20
23	Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. <i>Cancer Cell</i> , 2017, 32, 474-489.e6.	16.8	483
24	Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer. <i>Prostate</i> , 2016, 76, 325-334.	2.3	25
25	Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma-Like by Reprogramming. <i>Journal of Cellular Physiology</i> , 2016, 231, 2040-2047.	4.1	14
26	Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts. <i>Prostate</i> , 2015, 75, 303-313.	2.3	31
27	Establishment and serial passage of cell cultures derived from LuCaP xenografts. <i>Prostate</i> , 2013, 73, 1251-1262.	2.3	27
28	Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling. <i>PLoS ONE</i> , 2013, 8, e78881.	2.5	60
29	Methodology to Investigate Androgen-Sensitive and Castration-Resistant Human Prostate Cancer Xenografts in Preclinical Setting. <i>Methods in Molecular Biology</i> , 2011, 776, 295-312.	0.9	3
30	Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. <i>Journal of Clinical Investigation</i> , 2010, 120, 2715-2730.	8.2	633